Cargando…
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175222/ https://www.ncbi.nlm.nih.gov/pubmed/32143496 http://dx.doi.org/10.3390/biom10030399 |